This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Degenerative mitral valve disease is common. Up to a quarter of patients with degenerative mitral valve disease may be asymptomatic despite having severe valve regurgitation. Efforts should focus on establishing high-volume regional centres of excellence for mitral valve repair.
In an era of rapidly expanding use of transcatheter aortic valve implantation (TAVI), the management of patients with bicuspid aortic valve (BAV) disease is far less well established than in those with trileaflet anatomy.
Background Bicuspid aortic valve (BAV) is the most common congenital heart defect in adults, often leading to complications such as thoracic aortic aneurysms and aortic stenosis. While BAV is frequently associated with 22q11.2
Genetic variants linked to a rare form of bicuspid aortic valve disease that affects young adults and can lead to dangerous and potentially life-threatening aortic complications have been identified by researchers at UTHealth Houston.
Bicuspid aortic valve (BAV), the most common congenital cardiac anomaly, predisposes individuals to aortic stenosis and regurgitation due to valve degeneration. Abnormal hemodynamics, arterial wall characteristics, and genetic factors contribute to ascending aorta dilatation, potentially leading to severe complications like aortic dissection.
Columbia University Irving Medical Center’s Division of Cardiology has announced its launch of the Mitral & Tricuspid Center. Tricuspid and mitral valves are debilitating conditions that can lead to arrhythmias, hypertension, and heart failure.
BackgroundPatients with severe mitral regurgitation and cardiogenic shock demonstrate a poor prognosis. Device success was achieved in 86% (95% CI, 85%87%) and mitral regurgitation 2+ in 89% (95% CI: 88%90%). A total of 24 studies and 5428 patients were included, with a mean age of 71.23.3
session, "Robotic Cardiac Surgery: The Future Is Now," Dr. Tedy Sawma will discuss how mitral regurgitation, increasingly common in aging populations, presents unique challenges for older patients considering surgical treatment options. In todays 11:30 a.m.
Large and rare duplications and deletions in a chromosome region known as 22q11.2 , which involves genes that regulate cardiac development, are linked to nonsyndromic bicuspid aortic valve disease.
Barr’s death at 39 from sudden cardiac arrest was caused by mitral valve prolapse—a heart valve defect that can affect the heart’s ability to pump blood. In the past, heart surgeons corrected a faulty mitral valve by replacing it with an artificial one during open-heart surgery. It can, in some cases, lead to death.
Mashable) The SGLT2 inhibitor ertugliflozin (Steglatro) showed promise for the reduction of functional mitral. (MedPage Today) -- The Apple Watch atrial fibrillation feature got added to FDA's list of qualified devices for use in clinical studies.
milla1cf Mon, 06/03/2024 - 12:36 June 3, 2024 — HighLife SAS , a medtech company focused on the development of a novel Trans-Septal Mitral Valve Replacement (“TSMVR”) system to treat patients suffering from moderate to severe Mitral Regurgitation (MR), announced today that the U.S. I am honored to lead the HighLife pivotal study.
Background Mitral valve repair (MVr) is the gold standard treatment for degenerative mitral regurgitation, yet there is ongoing controversy regarding optimal anti-thrombotic therapy post-MVr.
This knowledge gap may result in under-recognition and subsequent delays in diagnosis.Case summaryA 76-year-old female was scheduled in our department for mitral transcatheter edge-to-edge repair (TEER).
Food and Drug Administratio n ( FDA ) for the AltaValve System , a transcatheter mitral valve replacement (TMVR) device. MR occurs when blood flows backward through the mitral valve and into the atrium each time the left ventricle contracts. milla1cf Wed, 05/08/2024 - 11:02 May 8, 2024 — 4C Medical Technologies, Inc. ("4C
BackgroundThis study examines the anatomical characteristics of the mitral isthmus (MI) and its spatial relationship with the esophagus in patients undergoing atrial fibrillation ablation, using cardiovascular computed tomographic angiography (CTA).
Despite the promising results of both MitraClip and PASCAL systems for the treatment of mitral regurgitation (MR), there is limited data on the comparison of both systems regarding their safety and efficacy.
For 27-year-old Rachael Boyle, heart health was a familiar topic. Her younger brother had experienced heart problems as a teenager, but she had always been healthy. That all changed when she fell ill in April 2024.
Transcript of the video: Closure line of aortic valve on M-Mode echocardiogram, is seen as central line, while in bicuspid aortic valve, it is an eccentric closure, nearer to one of the walls of the aorta. That is an important feature of bicuspid aortic valve on M-Mode echocardiogram. So this is a premature beat. is the normal range.
Whether this association is present in calcific mitral stenosis remains unknown.Methods and ResultsThis study was a retrospective analysis of consecutive patients with mitral stenosis secondary to mitral annular calcification (MAC) undergoing transseptal catheterization. Median diastolic mitral valve gradient was 9.4±3.4
1, 2024 — Researchers at UTHealth Houston have identified genetic variants linked to a rare form of bicuspid aortic valve disease that affects young adults and can lead to dangerous and potentially life-threatening aortic complications. tim.hodson Wed, 09/04/2024 - 15:53 Sept.
The co-occurrence of a bicuspid aortic valve (BAV) with TSC is exceedingly rare.Case summaryWe report the case of a 26-year-old woman with genetically confirmed TSC, harboring a novel pathogenic variant in the TSC2 gene. multi-system characteristics of TSC were also presented, affecting skin, brain, lung, kidney, and bone.
Bicuspid aortic valve (BAV) is a common congenital heart condition that can lead to some valve-related complications, such as aortic stenosis and/or regurgitation, and is often associated with aortic root dilation.
Totally endoscopic robotic mitral valve repair is the least invasive surgical therapy for mitral valve disease. Robotic mitral valve surgery demonstrates faster recovery with shorter hospital stays, less morbidity, and equivalent mortality and mid-term durability compared to sternotomy.
What are the procedural and clinical outcomes of balloon-expandable valves (BEVs) and self-expanding valves (SEVs) in Sievers type 1 bicuspid aortic valve (BAV) stenosis?
Sudden cardiac arrest (SCA) risk stratification in patients with mitral valve prolapse (MVP) may be complicated by other potential causes of arrhythmia.
The mitral valve complex consists of the mitral annulus, mitral valve leaflets, the chordae tendineae and the papillary muscles. The mitral leaflets are the anterior and posterior leaflets. The post Anatomy of the Mitral Valve appeared first on All About Cardiovascular System and Disorders.
The following are key points to remember from a state-of-the-art review on the evolving concept of secondary mitral regurgitation (MR) phenotypes and lessons from the mitral transcatheter edge-to-edge repair (M-TEER) trials.
BACKGROUND:Transcatheter edge-to-edge mitral valve (MV) repair (TEER) is an effective treatment for patients with primary mitral regurgitation at prohibitive risk for surgical MV repair (MVr). Circulation: Cardiovascular Interventions, Ahead of Print.
Current surgical options in mitral valve IE include mitral valve repair (MVr) or replacement (M. Valve infective endocarditis (IE) is a potentially life-threatening condition that affects patients’ livelihoods.
In patients with failed mitral valve prostheses, what are the clinical outcomes of redo surgical mitral valve replacement (SMVR) versus transcatheter mitral valve replacement (TMVR), and how does hospital case volume relate to outcomes?
Transcript of the video: Now we will discuss echocardiogram in mitral valve prolapse. But, even though mitral valve prolapse can be detected echocardiographically in many cases, there may not be significant regurgitation and symptoms in many of them. So we will see some of the features of mitral regurgitation.
based Duke Health has performed the world's first living mitral valve replacement after a heart transplant patient donated healthy valves from their original heart to two other patients. A team from Durham, N.C.-based
Video 8 in 8 Series: Latin Heart Rounds on Mitral Annular Disjunction kchalko Mon, 05/20/2024 - 08:24 In this 8x8 video (presented in Spanish), Dr. Juan Crestanello, chief of cardiac surgery at Mayo Clinic in Rochester, MN, discusses annular disjunction of the mitral valve, its medical and surgical implications, and also the operative techniques used (..)
Two studies analyzing data from the STS/ACC TVT Registry exploring out-of-hospital 30-day mortality after mitral transcatheter edge-to-edge repair (TEER) and one-year cause-specific mortality after TAVR were published in JACC: Cardiovascular Interventions on March 19.
Severe secondary mitral regurgitation carries a poor prognosis with one in five patients dying within 12 months of diagnosis. Optimal guideline-directed medical therapy is the mainstay therapy and has been shown to reduce the severity of mitral regurgitation in 40–45% of patients. to reduce heart failure hospitalisation and 5.9
What are the bleeding and thrombotic events associated with direct oral anticoagulants (DOACs) or vitamin K antagonists (VKAs) in a prospective cohort of patients who underwent transcatheter mitral valve replacement (TMVR)?
Introduction Volume overload from mitral regurgitation can result in left ventricular systolic dysfunction. We compared volumetric CT-based and 2D echocardiographic indices of LV size and function as predictors of post-operative systolic dysfunction following mitral repair. Validation with prospective study is warranted.
Mitral annular calcification (MAC) is common in the setting of chronic kidney disease and aging. Previously presumed "degenerative" in etiology, cardiac/vascular calcification is now understood to be inflammatory, involving osteoblastic transformation of myofibroblasts.
In this episode, the focus is on mitral valve disease. In these panel discussions, host Andrea Price MS, AACC brings together Bailey Estes MSN, AGNP-C, Nicole Dellise, NP, and Kristen deAlmeida, PharmD to explore best practices related to structural heart disease.
What is the prevalence and what are the characteristics of mitral valve prolapse (MVP) in a large cohort of patients with unexplained cardiac arrest (UCA)?
Columbia and Cornell researchers developed an echo AI model that could improve the difficult task of mitral regurgitation diagnosis, and might even represent an AI-driven step towards enhancing all valvular regurgitation assessments. The post New Echo AI Model Could Streamline Mitral Regurgitation Diagnosis appeared first on Cardiac Wire.
RESHAPE-HF2 shows mitral transcatheter edge-to-edge repair (M-TEER) reduces heart failure hospitalizations and improves quality of life vs optimal medical therapy alone.
The goal of the MATTERHORN trial was to evaluate mitral transcatheter edge-to-edge repair (M-TEER) compared with surgical mitral valve repair among patients with secondary mitral regurgitation (MR).
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content